|
Feb 19, 00:39
|
End of Apogee (APGE) Drug Collaboration Leads to Revised Analyst Expectations
|
N/A |
—
|
—
|
No analysis
|
|
Feb 19, 00:38
|
Amgen Details Oncology R&D Push, IMDELLTRA Expansion and LUMAKRAS Updates at Citi Summit
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 18:14
|
Amgen Inc. (AMGN) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
|
N/A |
—
|
—
|
No analysis
|
|
Feb 18, 08:27
|
Piper Sandler Maintains Overweight on Amgen, Raises Price Target to $432
|
N/A |
—
|
—
|
No analysis
|
|
Feb 17, 16:30
|
MATTERWORKS, INC. ANNOUNCES UPDATE TO LEADERSHIP TEAM
|
N/A |
—
|
—
|
No analysis
|
|
Feb 14, 06:09
|
Is UPLIZNA’s EU Approval Reframing Amgen’s Rare Disease Strategy And Investment Case (AMGN)?
|
N/A |
—
|
✓
|
# AMGN News Report — 2026-02-14
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | AMGN |
| **Date** | 2026-02-14 |
| **Total Articles...
|
|
Feb 14, 03:02
|
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 21:01
|
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 17:50
|
Amgen Files For Mixed Shelf Offering; Size Not Disclosed
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 14:57
|
Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 06:13
|
Prices, pipelines and patent cliffs: Inside pharma's big reset
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 04:39
|
1 Large-Cap Stock Worth Your Attention and 2 We Avoid
|
N/A |
—
|
—
|
No analysis
|
|
Feb 13, 01:14
|
Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 19:34
|
Amgen Inc. (AMGN) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
|
N/A |
—
|
—
|
No analysis
|
|
Feb 12, 18:56
|
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
|
N/A |
—
|
✓
|
# AMGN News Report — 2026-02-12
## Overview
| Metric | Value |
|--------|-------|
| **Ticker** | AMGN |
| **Date** | 2026-02-12 |
| **Total Articles...
|
|
Feb 12, 12:55
|
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 16:49
|
Asthma Drugs Market to Reach USD 41.18 Billion by 2035 | Biologic Therapies Accelerate Shift Toward Targeted Treatment Says Astute Analytica
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 14:55
|
Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose
|
N/A |
—
|
—
|
No analysis
|
|
Feb 11, 00:55
|
Review & Preview: Consumers Show Strain
|
N/A |
—
|
—
|
No analysis
|